Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
received:
28
07
2021
revised:
29
08
2021
accepted:
14
09
2021
pubmed:
26
9
2021
medline:
8
4
2022
entrez:
25
9
2021
Statut:
ppublish
Résumé
Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as "recruiting" or "not yet recruiting" as of February 2021.
Identifiants
pubmed: 34561269
pii: 1078-0432.CCR-21-2750
doi: 10.1158/1078-0432.CCR-21-2750
pmc: PMC9044253
mid: NIHMS1796919
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-602Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009615
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Neuro Oncol. 2019 Feb 19;21(3):348-359
pubmed: 30500939
J Clin Oncol. 2017 Nov 20;35(33):3737-3744
pubmed: 28968170
Neuro Oncol. 2009 Oct;11(5):550-5
pubmed: 19332770
Clin Cancer Res. 2021 May 1;27(9):2394-2399
pubmed: 33563632
Neuro Oncol. 2018 May 18;20(6):838-847
pubmed: 29077941
Neuro Oncol. 2018 Apr 9;20(5):674-686
pubmed: 29106665
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Cancer Cell. 2018 Jan 8;33(1):152
pubmed: 29316430
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Neuro Oncol. 2019 Jan 1;21(1):95-105
pubmed: 30277538
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
Neuro Oncol. 2020 Oct 14;22(10):1422-1424
pubmed: 32506123
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Neuro Oncol. 2015 Jun;17(6):854-61
pubmed: 25586468
J Clin Oncol. 2011 Jan 20;29(3):337-44
pubmed: 21149665
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
Neuro Oncol. 2017 Apr 1;19(4):469-474
pubmed: 28388713
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520
pubmed: 30733593
Front Oncol. 2020 Sep 18;10:563840
pubmed: 33072591
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Cell. 2020 Jan 9;180(1):188-204.e22
pubmed: 31883794
Neurooncol Adv. 2021 Feb 12;3(1):vdab029
pubmed: 34042101
J Clin Oncol. 2009 Mar 10;27(8):1257-61
pubmed: 19188676
JCO Precis Oncol. 2019 Mar 27;3:
pubmed: 32914038
J Clin Oncol. 2017 Nov 20;35(33):3760-3773
pubmed: 28968165
Cancer. 2020 Dec 1;126(23):5022-5029
pubmed: 32970346
Neuro Oncol. 2021 Feb 25;23(2):240-250
pubmed: 33130898
J Clin Oncol. 2010 Nov 1;28(31):4722-9
pubmed: 20921459
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Sci Transl Med. 2016 Jun 1;8(341):341ra75
pubmed: 27252174
Neuro Oncol. 2018 Jan 10;20(1):113-122
pubmed: 29016865
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
J Clin Oncol. 2010 Apr 10;28(11):1936-41
pubmed: 20212253
Am J Clin Oncol. 2018 Feb;41(2):191-196
pubmed: 28832384
Neuro Oncol. 2017 Jul 01;19(7):965-975
pubmed: 28039367
Cancer Discov. 2020 Jul;10(7):964-979
pubmed: 32253265
Neuro Oncol. 2010 Mar;12(3):233-42
pubmed: 20167811
Neuro Oncol. 2019 Jan 1;21(1):59-70
pubmed: 30053126
Neurooncol Adv. 2021 Feb 26;3(1):vdab008
pubmed: 33665615
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
Neuro Oncol. 2018 Sep 3;20(10):1383-1392
pubmed: 29762717
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Neuro Oncol. 2019 Oct 9;21(10):1239-1249
pubmed: 31155679
Clin Cancer Res. 2018 Feb 15;24(4):737-743
pubmed: 28814435
Cancer Treat Rev. 2020 Jul;87:102029
pubmed: 32408220
Clin Cancer Res. 2019 Aug 15;25(16):4993-5001
pubmed: 31175098
JAMA Oncol. 2020 Dec 1;6(12):1939-1946
pubmed: 33119048
Neuro Oncol. 2019 Sep 6;21(9):1100-1117
pubmed: 31175826
Expert Rev Anticancer Ther. 2018 Oct;18(10):1031-1040
pubmed: 29973092
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
Neuro Oncol. 2021 Apr 12;23(4):537-538
pubmed: 33704490
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34215688
Neuro Oncol. 2011 Mar;13(3):324-33
pubmed: 21149254
Eur J Cancer. 1997 Aug;33(9):1361-3
pubmed: 9337674
Radiat Oncol. 2017 Jan 3;12(1):1
pubmed: 28049492
J Immunother Cancer. 2020 May;8(1):
pubmed: 32474411
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Neuro Oncol. 2018 May 18;20(6):848-857
pubmed: 29036412
Neuro Oncol. 2020 Dec 18;22(12):1742-1756
pubmed: 32897363
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Neurooncol Adv. 2020 Dec 22;3(1):vdaa171
pubmed: 33543145
Neuro Oncol. 2020 Nov 26;22(11):1568-1579
pubmed: 32598442
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
J Natl Cancer Inst. 2019 Dec 1;111(12):1255-1262
pubmed: 31218346
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Front Neurol. 2019 May 07;10:460
pubmed: 31133966
Clin Cancer Res. 2010 Apr 15;16(8):2443-9
pubmed: 20371685
Neuro Oncol. 2018 Jul 5;20(8):1034-1043
pubmed: 29518210
Neuro Oncol. 2020 May 15;22(5):601-612
pubmed: 31974566
Neurooncol Adv. 2020 Oct 24;3(1):vdaa145
pubmed: 33543142